Efficacy and safety of peginterferon beta-1a (CinnaGen) versus CinnoVex® (CinnaGen) in reducing the annualized relapse rate (ARR) in participants with relapsing-remitting multiple sclerosis: A phase III, randomized, parallel, non-inferiority study.
Phase of Trial: Phase III
Latest Information Update: 22 Oct 2018
At a glance
- Drugs Peginterferon beta-1a (Primary) ; Peginterferon beta-1a
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors CinnaGen
- 11 Oct 2018 Planned number of patients changed from 152 to 168.
- 22 Feb 2018 Status changed from not yet recruiting to recruiting.
- 09 Feb 2017 New trial record